Creating advanced probiotics to deliver medications effectively
Official title: Engineering next generation probiotics for delivery of therapeutics
Funded at Medosome Biotec, LLC · NIH-10697438 · Data updated 2026-11-12
This study is testing a new kind of probiotic that could help deliver important medications directly to your body through your mouth, making it easier and safer for you to get the treatment you need.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medosome Biotec, LLC NIH-funded |
| Lab location | 1 site (Alachua, UNITED STATES) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $325,000 |
| NIH project number | 1R43TR004525-01 |
| Project ID | NIH-10697438 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with chronic diseases that require peptide or protein-based therapies.
✕Less likely to help
Patients who do not require peptide or protein therapeutics or those who are not suitable for probiotic treatments may not benefit from this research.
What this research studies
This research focuses on developing a new type of probiotic that can safely and effectively deliver peptide and protein drugs through oral administration. The innovative platform aims to overcome the challenges of poor bioavailability and stability that often limit the effectiveness of these therapeutics. By using engineered probiotics, the project seeks to enhance the delivery of these drugs directly to the target tissues, making treatment easier and more efficient for patients. The research will also address safety concerns related to the use of engineered microbes in clinical applications.
Why it matters
Potential benefit: If successful, this research could significantly improve the effectiveness of oral medications for various chronic diseases.
How similar studies have gone: Previous research has shown promise in using probiotics for drug delivery, but this approach aims to enhance safety and stability, making it a novel advancement.
Where this research is happening
-
Medosome Biotec, LLC
Alachua, United States Active
Researchers
- Principal investigator: Wagner, Richard — Medosome Biotec, LLC
- Study coordinator: Wagner, Richard
Related research
Other NIH-funded projects on the same topics.
-
GLP-1 producing engineered probiotics to help manage metabolic diseases
A research project aims to create probiotic bacteria that constantly deliver GLP-1 to help people with type 2 diabetes and obesity manage their condition.
-
Investigating a new therapy for septic shock using a drug called Dichloroacetate.
This study is looking at how a drug called Dichloroacetate (DCA) might help immune cells work better during severe sepsis, a serious condition, by testing it in pigs to see if it’s safe and effective for future use in people.
-
Developing a new test to measure drug resistance in hepatitis C virus
This study is working on a new test that helps doctors find out if the hepatitis C virus in patients has changed in a way that makes it resistant to treatments, so they can choose the best medicine for people who haven't had success with previous therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.